Business
Codexis Expands and Strengthens its Leadership Team with Two Executive Hires
REDWOOD CITY, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces
About this update from Codexis, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- Codexis, Inc., a leading protein engineering company and developer of novel biotherapeutics, announces the appointment of Stefan Lutz, Ph.D. as Senior Vice President, Research and Karl A. Schoene, Ph.D. as Senior Vice President, Development & Operations, effective immediately. Both positions are newly created and both report to Codexis President and CEO John Nicols. \n\n \n \n \n \n \n \n \n \n \n \n \n Karl A. Schoene, Ph.D., Codexis Senior Vice President, Development & Operations\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Stefan Lutz, Ph.D., Codexis Senior Vice President, Research\n \n \n \n \n \n \n \n \n\n “We are fortunate to welcome two extraordinary professionals to lead functions that are critical to future growth in both our Performance Enzymes and our Novel Biotherapeutics business segments,” stated Mr. Nicols. “Stefan and Karl will serve as key members of our leadership team, and we look forward to their many contributions as we expand and grow our business. “Stefan brings unprecedented knowledge in protein engineering and synthetic biology, which are at the core of our R&D activities. He and his accomplishments are well-known and highly regarded within our industry and by many of our scientists at Codexis. After years in academia and as a consultant, he has a keen interest in applying his knowledge full time in a commercial setting. His drive and expertise make him ideally qualified to lead our research team, which represents over half of our employees, and to advance the discovery of proteins that are the engine for our product growth and business expansion,” he said. “Karl has proven success in leading dynamic, multi-functional teams and growing numerous global specialty chemical platform businesses in a wide variety of settings over his substantial career,” said Mr. Nicols. “This broad-based experience will be highly valuable in developing, scaling and commercializing Codexis’ growing suite of products discovered in small scale under our CodeEvolver® process. Karl also brings a wealth of commercial stage expertise beneficial to optimizing and leading the global manufacturing and supply chain operations that continue to build as the company grows.” Dr. Lutz most recently was a Professor and Chair of the Chemistry Department at Emory University, having joine...